Takeda Pharmaceutical Company (TAK)

Takeda Pharmaceutical Company (TAK) Financial Statements


Takeda Pharmaceutical Company Financial Overview

Takeda Pharmaceutical Company's market cap is currently ―. The company's EPS TTM is $0.449; its P/E ratio is 31.08; and it has a dividend yield of 4.17%. Takeda Pharmaceutical Company is scheduled to report earnings on February 1, 2024, and the estimated EPS forecast is $0.10. See an overview of income statement, balance sheet, and cash flow financials.
Mar 23Dec 22Sep 22Jun 22Mar 22
Income Statement-
Total Revenue-¥ 1.10T¥ 1.00T¥ 972.47B¥ 873.29B
Gross Profit-¥ 760.58B¥ 696.86B¥ 679.58B¥ 564.91B
EBIT-¥ 186.90B¥ 118.35B¥ 210.94B¥ -75.15B
EBITDA-¥ 363.78B¥ 286.18B¥ 369.23B¥ 77.12B
Net Income Common Stockholders-¥ 119.13B¥ 61.74B¥ 105.01B¥ -11.36B
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments¥ 632.70B¥ 726.61B¥ 830.07B¥ 664.53B¥ 875.00B
Total Assets¥ 13.96T¥ 13.50T¥ 14.59T¥ 14.07T¥ 13.18T
Total Debt¥ 4.38T¥ 4.29T¥ 4.74T¥ 4.60T¥ 4.35T
Net Debt¥ 3.75T¥ 3.56T¥ 3.91T¥ 3.94T¥ 3.47T
Total Liabilities¥ 9.28T¥ 7.33T¥ 7.88T¥ 7.75T¥ 7.49T
Stockholders Equity¥ 4.68T¥ 6.18T¥ 6.71T¥ 6.32T¥ 5.68T
Cash Flow-
Free Cash Flow-¥ 327.61B¥ 180.38B¥ -14.13B¥ 323.76B
Operating Cash Flow-¥ 378.23B¥ 220.99B¥ 84.24B¥ 375.58B
Investing Cash Flow-¥ -46.69B¥ -27.21B¥ -94.71B¥ -25.64B
Financing Cash Flow-¥ -434.95B¥ -51.88B¥ -215.72B¥ -243.80B
Currency in JPY

Takeda Pharmaceutical Company Earnings and Revenue History

Takeda Pharmaceutical Company Debt to Assets

Takeda Pharmaceutical Company Cash Flow

Takeda Pharmaceutical Company Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis